1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Devyser Diagnostics AB (publ)

Devyser Diagnostics AB (publ)

DVYSR.ST
Devyser Diagnostics AB (publ)SE flagStockholm Stock Exchange
60.30
SEK
+2.10
- -
1.00BMarket Cap
Devyser Diagnostics AB (publ)
DVYSR.ST
(Stockholm Stock Exchange)

Recent

price

60.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
4.21
5.62
6.02
8.32
7.95
10.46
13.23
15.1
14.22
Revenue per Share
- -
0.05
0.61
-1
-1.85
-2.89
-3.31
-3.75
-0.51
-2.76
Basic EPS, GAAP
- -
0.08
0.47
-0.26
-2.25
-4.16
-6.29
-7.78
-3.74
-5.81
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.71
-0.1
-1.09
-2.86
-4.84
-7.99
-11.46
-11.69
-12.43
Book Value per Share
- -
1.32
1.45
1.5
35.48
24.59
20.33
15.06
11.67
12.38
Tangible Book Value per Share
- -
11
11
11
11
16
16
16
17
17
Basic Weighted Avg Shares
- -
48
64
66
93
127
169
217
250
235
Sales/Revenue/Turnover
- -
-2.49
13.82
-16.69
-25.1
-43.29
-33.25
-28.86
4.59
-14.84
Operating Margin (%)
- -
3
5
13
6
8
13
28
27
28
Depreciation Expense
- -
1
7
-11
-21
-46
-54
-62
-8
-46
Net Income, GAAP
- -
- -
27.22
- -
- -
- -
- -
- -
- -
35
Effective Tax Rate (%)
- -
1.08
10.9
-16.61
-22.17
-36.33
-31.66
-28.35
-3.35
-19.4
Profit Margin (%)
20
18
17
12
383
361
279
180
133
142
Working Capital
6
8
20
15
10
16
57
45
38
41
LT Debt
29
30
37
31
417
431
385
349
354
338
Total Equity
- -
- -
12.35
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
62.41
- -
- -
- -
- -
- -
- -
-29.8
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
14
14
13
LT Borrowings
- -
- -
- -
LT Finance Leases
45
43
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
1,943
1,679
2,099

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
252
220
216
Cash, Cash Equivalents & STI
144
114
100
Accounts Receivable, Net
51
44
53
Inventories
30
36
39
Total Current Liabilities
73
74
75
Payables & Accruals
- -
- -
- -
ST Debt
14
14
13
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
247.8%
1.52%
Free Cash Flow
- -
199.3%
-51.41%
Net Income, GAAP
- -
31.36%
-86.34%
Sales/Revenue/Turnover
- -
31.02%
15.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51
53
49
64
217
2025
55
67
72
- -
250
2026
62
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.75
-1.4
-1.41
-0.19
-3.75
2025
-1.24
0.08
0.82
- -
-0.51
2026
0.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ScreenPro Security Inc. (SCRN.CN)
WuXi AppTec Co., Ltd. (WUXIF)
Burning Rock Biotech Limited (BNR)
Twist Bioscience Corporation (TWST)
BCAL Diagnostics Limited (BDX.AX)
CelLBxHealth plc (ANPCY)
Business
Devyser Diagnostics AB (publ) (DVYSR.ST) develops, manufactures and sells diagnostic kits and software solutions for advanced DNA testing in hereditary diseases, oncology and post-transplantation monitoring. The company offers next-generation sequencing (NGS)-based assays including Devyser Genomic Blood Typing for comprehensive genetic blood group analysis covering red blood cell, human platelet antigen and human neutrophil antigen systems; Devyser HLA Loss for post-transplant research; Devyser CFTR for complete sequencing of the CFTR gene in cystic fibrosis; tests for thalassemia, BRCA in breast, colorectal and ovarian cancer; prenatal aneuploidy and non-invasive fetal RhD screening; cardiovascular panels for familial hypercholesterolemia; hematology panels for blood conditions; and chimerism and cell-free DNA monitoring for transplant patients such as One Lambda Devyser Chimerism and Devyser Accept cfDNA; alongside Amplicon Suite and Advyser software for data analysis. Products target routine diagnostic laboratories serving personalized cancer therapies, genetic disease diagnosis and transplant follow-up, with sales through direct channels and distributors to over 65 countries across Europe, the Middle East, Africa, Asia-Pacific, North and South America. Devyser Diagnostics AB (publ), founded in 2004, is headquartered in Stockholm, Sweden, and operates a CLIA-certified laboratory in Atlanta, Georgia, with in-house sales offices in Europe and the US. Recent developments include the global launch of Devyser Genomic Blood Typing and Devyser HLA Loss in June 2025; IVDR certification for Devyser CFTR in November 2025 and earlier products like kidney transplant monitoring assays; a major SEK 16.8 million tender win in Italy in February 2025 for CFTR, BRCA and thalassemia NGS tests representing 30% growth over prior contract; partnership with Quest Diagnostics in Q3 2025 to add fetal RhD test to its US portfolio; expanded collaboration with Thermo Fisher Scientific for FDA approval pursuit of kidney transplant cfDNA test; CMS pricing approval for PrenatalDetect RhD in the US; and appointment of Jan Wahlström as CEO in August 2025.